Ventola C Lee
P T. 2010 Jan;35(1):24-9.
This article presents the third in a series of three interviews that P&T conducted with several members of the American Society of Health-System Pharmacists (ASHP) Expert Panel on Formulary Management.In 2008, ASHP convened this panel of experts to develop revised guidelines for P&T committee and formulary management to replace the previous guidance issued in 1991.1 These revised guidelines include recommendations concerning the review and evaluation of drugs for formulary inclusion, pharmacoeconomic assessments, therapeutic interchange, medication-use evaluations (MUEs), management of drug shortages, and many other important topics.In this series, ASHP experts discuss P&T committee and formulary management guidelines in their respective institutions as well as other observations and insights. In Part 3, the author interviews Sabrina Cole, PharmD, Clinical Specialist, Drug Information, at the Grady Health System in Atlanta, Georgia.
本文呈现的是药品与治疗学委员会（P&T）对美国卫生系统药师协会（ASHP）处方集管理专家小组多名成员进行的三场系列访谈中的第三场。2008年，ASHP召集了这个专家小组，以制定P&T委员会和处方集管理的修订指南，取代1991年发布的先前指南。这些修订指南包括有关审查和评估纳入处方集的药物、药物经济学评估、治疗性替换、用药评估（MUEs）、药品短缺管理以及许多其他重要主题的建议。在这个系列中，ASHP专家讨论了各自机构中的P&T委员会和处方集管理指南以及其他观察结果和见解。在第三部分中，作者采访了佐治亚州亚特兰大格雷迪健康系统的药学博士、药物信息临床专家萨布丽娜·科尔。
